[go: up one dir, main page]

ATE374788T1 - Polysialinsäurederivate - Google Patents

Polysialinsäurederivate

Info

Publication number
ATE374788T1
ATE374788T1 AT04768054T AT04768054T ATE374788T1 AT E374788 T1 ATE374788 T1 AT E374788T1 AT 04768054 T AT04768054 T AT 04768054T AT 04768054 T AT04768054 T AT 04768054T AT E374788 T1 ATE374788 T1 AT E374788T1
Authority
AT
Austria
Prior art keywords
polysialic acid
acid derivatives
functional group
instance
hetero
Prior art date
Application number
AT04768054T
Other languages
English (en)
Inventor
Dale H Hreczuk-Hirst
Sanjay Jain
Peter Laing
Gregory Gregoriadis
Iaonnis Papaioannou
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Application granted granted Critical
Publication of ATE374788T1 publication Critical patent/ATE374788T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
AT04768054T 2003-08-12 2004-08-12 Polysialinsäurederivate ATE374788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03254988 2003-08-12
EP03255200 2003-08-21

Publications (1)

Publication Number Publication Date
ATE374788T1 true ATE374788T1 (de) 2007-10-15

Family

ID=34196160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768054T ATE374788T1 (de) 2003-08-12 2004-08-12 Polysialinsäurederivate

Country Status (9)

Country Link
US (4) US7691826B2 (de)
EP (1) EP1654289B1 (de)
JP (1) JP2007501888A (de)
KR (1) KR101270692B1 (de)
AT (1) ATE374788T1 (de)
DE (1) DE602004009314T2 (de)
ES (1) ES2294535T3 (de)
RU (1) RU2327703C2 (de)
WO (1) WO2005016973A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
DE602004009314T2 (de) * 2003-08-12 2008-02-07 Lipoxen Technologies Ltd. Polysialinsäurederivate
WO2006016161A1 (en) 2004-08-12 2006-02-16 Lipoxen Technologies Limited Fractionation of charged polysaccharide
EP3184551A1 (de) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialinsäurederivate
CN103626884B (zh) 2005-02-23 2016-05-18 利普生技术有限公司 用于蛋白质衍生和缀合的活化的唾液酸衍生物
PL1877099T3 (pl) 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
JP5096466B2 (ja) 2006-07-25 2012-12-12 リポクセン テクノロジーズ リミテッド Ｎ末端ポリシアリル化
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
KR101654375B1 (ko) * 2007-06-26 2016-09-05 박스알타 인코퍼레이티드 가수분해성 중합체 ｆｍｏｃ-링커
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
TR201909909T4 (tr) 2008-12-16 2019-07-22 Genzyme Corp Oligosakkarit- protein konjugeleri.
TW201042257A (en) * 2009-05-26 2010-12-01 Baxter Int Detection of antibody that binds to water soluble polymer-modified polypeptides
NZ597600A (en) * 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
MX2012001207A (es) 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
NZ623810A (en) * 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
JP5566226B2 (ja) * 2009-09-03 2014-08-06 旭化成株式会社 １１糖シアリルオリゴ糖ペプチドの製造方法
RU2522846C2 (ru) * 2009-11-30 2014-07-20 Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации Лекарственный препарат и способ улучшения реологических свойств мокроты и ингаляционное применение такого препарата
JP5285022B2 (ja) * 2010-04-30 2013-09-11 旭化成株式会社 糖ペプチド誘導体及びその製造方法
RU2559522C2 (ru) * 2010-11-29 2015-08-10 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Ингаляционная лекарственная форма полисиалированной дезоксирибонуклеазы i человека и способ ее получения
JP5680576B2 (ja) * 2011-03-03 2015-03-04 旭化成株式会社 １１糖シアリルオリゴ糖アスパラギンの製造方法
CA3012117A1 (en) * 2011-05-27 2012-12-06 Baxalta Incorporated Fusions of psa with serpins and other therapeutic proteins
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US20200179524A1 (en) 2017-04-25 2020-06-11 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
ES2711669A1 (es) * 2017-11-02 2019-05-06 Univ Santiago Compostela Sistemas de liberacion de farmacos de acido polisialico y metodos
WO2020099513A1 (en) 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU675053A1 (ru) * 1977-08-10 1979-07-25 Институт Белка Ан Ссср 9-Йодацетамидо-метил-антрацен в качестве люминесцентной метки дл белков и белковоподобных полимеров
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
ATE372783T1 (de) * 1993-01-22 2007-09-15 Sloan Kettering Inst Cancer Gangliosid-klh-konjugatimpfstoffe mit qs-21 zur verzögerung des wiederauftretens eines melanoms
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
EP1335931B1 (de) * 2000-05-16 2005-12-21 Lipoxen Technologies Limited Derivatisierung von proteinen in wässrigem lösungsmittel
DE602004009314T2 (de) * 2003-08-12 2008-02-07 Lipoxen Technologies Ltd. Polysialinsäurederivate
EP3184551A1 (de) * 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialinsäurederivate
JP5096466B2 (ja) * 2006-07-25 2012-12-12 リポクセン テクノロジーズ リミテッド Ｎ末端ポリシアリル化

Also Published As

Publication number Publication date
KR20060085329A (ko) 2006-07-26
KR101270692B1 (ko) 2013-06-03
US20060270830A1 (en) 2006-11-30
RU2327703C2 (ru) 2008-06-27
WO2005016973A1 (en) 2005-02-24
US20150307633A1 (en) 2015-10-29
US20100221808A1 (en) 2010-09-02
US9102714B2 (en) 2015-08-11
RU2006107545A (ru) 2007-09-27
ES2294535T3 (es) 2008-04-01
EP1654289B1 (de) 2007-10-03
US20130144043A1 (en) 2013-06-06
EP1654289A1 (de) 2006-05-10
US7691826B2 (en) 2010-04-06
JP2007501888A (ja) 2007-02-01
DE602004009314T2 (de) 2008-02-07
US9920137B2 (en) 2018-03-20
DE602004009314D1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
ATE374788T1 (de) Polysialinsäurederivate
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
DE60321825D1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
DE69435105D1 (de) Derivate therapeutischer Peptide
CY1120644T1 (el) Μικροκαψουλες παρατεταμενης αποδεσμευσης με βαση πολυ(λακτιδιο-συν-γλυκολιδιο) που περιεχουν ενα πολυπεπτιδιο και ενα σακχαρο
CY1113537T1 (el) Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
CY1113353T1 (el) Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
ATE553780T1 (de) Ph-sensitives polymer
BRPI0408331A (pt) conjugado de polipetìdeo fisiologicamente ativo possuindo meia vida útil in vivo prolongada
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
ATE299134T1 (de) Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2006016168A3 (en) Sialic acid derivatives
BR0212363A (pt) Expressão hìbrida e em tandem de proteìnas de neisseria
ATE353864T1 (de) Fluorierung von proteinen und peptiden für positronemissionstomographie
EP1585756A4 (de) Verabreichung von sirnas
EP2298331A3 (de) Verwendung von Transthyretinpeptid-/-proteinfusionen zur Erhöhung der Serumshalbwertszeit von pharmakologisch aktiven Peptiden/Proteinen
BR0306675A (pt) Dispositivo para prover um número de produtos
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ATE227705T1 (de) Reagenz zur guanidinylierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties